A probiotic solution designed to reduce signs of gastrointestinal discomfort

Regularly experiencing gastrointestinal (GI) discomfort can be burdensome and can seriously impact our quality of life. Gut discomfort affects 1 in 5 people at some point in life, and twice as many women as men1. With only  between 5% and 19% of those affected finding comfort in available products,1 we embraced the challenge and developed a clinically studied solution4,5.

Powered by the unique 35624™ probiotic strain
Backed by more than 20 years of research

IBme™, refereed to as B. longum 35624™ in scientific literature, has been clinically shown to help ease abdominal pain3,4, bloating3, gas4, diarrhoea4 and constipation4. Issues that impact the quality of life of 20% of the population1. In their most recent global guidelines for Irritable Bowl Syndrome (IBS), the World Gastroenterology Organization acknowledged the IBme™ strain as being most efficacious strain for gut discomfort.11,3


An effective solution needed for a common problem

We all know someone with gastrointestinal discomfort. 1 in 5 of us are affected by it at some point in our lives, usually arising between the ages of 20 and 301. Market research indicates a need for products that help those that suffer improve their quality of life. Sufferers' dearest wishes are; to have the energy to enjoy life, improve sleep, experience relief, and to have consistency and predictability in their lives.1 Over 90% of consumers perceive these areas to be highly important, but difficult to achieve1.

As things stand, despite utilizing accessible treatments, more than 70% of individuals with GI discomfort experience frequent symptoms.1 40% of people living with abdominal pain, gas, bloating, and distention in the UK have had to cancel plans last-minute,1 while 26% have stayed at home all weekend due to their physical state.1

Key benefits of IBme™

Since day one, we’ve been committed to improving quality of life. With documented efficacy and clinical proof​ of action. IBme™ helps ease;

  • Abdominal pain,3,4 
  • Bloating3, 
  • Gas4
  • Diarrhea4,
  • Constipation,4

Backed by more than 20 years of research

IBme™, refereed to a 35624™ in scientific literature, is backed by more than 20 years of continuous research and testing, including gold-standard clinical trials.

These papers have been cited more than 1,000 times in scientific publications and peer-reviewed journals. Clinical evidence of the 35624™ probiotic strain has been included in numerous reviews8,9,10 with its efficacy and safety confirmed by studies across multiple countries.

A list of scientific publications on the 35624™ strain can be downloaded here.3,4,5


Recommended by doctors, trusted by consumers

Across China, Germany, and the United States, general practitioners and gastroenterologists are the most frequently contacted health care professionals for gut discomfort, and the most popular sources of information after symptom onset.1

Bifidobacterium longum 35624™ is listed as improving subjects’ global assessment of distressing gut symptoms in the World Gastroenterology Organisation’s Guidelines for Probiotics and Prebiotics11.


Backed by years of end user satisfaction

Consumers experience different feelings and pain-points at each ​step of their journey with digestive distress. As a result, a solution’s perceived efficacy is dictated by the issues and priorities of each individual.1 This is why it is so significant that both consumers and health care professionals validate the IBme's efficacy.

What makes IBme™ unique

IBme™ contains the bacterial strain 35624™. It is of human origin and part of the genus of bacteria called Bifidobacteria that are transferred from mother to baby at birth. It arrives in the gut alive, where it binds to the human epithelial cells and has a calming effect on the gut3,4,7,12,13.

Thousands of strains were put through a rigorous testing process to understand their properties. ​The 35624™ strain was isolated from the healthy mucosal tissue of the terminal ileum14, from within the gut of a female volunteer.

Out of all of the possible strains, number 35624™ emerged as the winner, proving to be the One-in-a-trillion solution to easing indications of gut discomfort3,4,5.

How the IBmeworks​

When ingested, IBme travels through the stomach and arrives in the small intestine, where it adheres to the intestinal epithelium and mucus layer3,4,7,12,13. Here, IBme provides a calming and strengthening coating that among other things, counters the impairment of the gut barrier function3,4,7,12,13.

Let’s create something extraordinary together 

If you’re ready to take your products the next level. We are here to help. From cutting edge biotechnology to specialist formulation and marketing. Whatever your dreams are for your brand. Together we can make it happen, let's talk.

Thanks for getting in contact, one of our team will respond to your query shortly.

We think you might also like these products



Reclaim "joie de vivre" with Pylopass, a postbiotic solution that may help reduce the load of H. pylori in the stomach.

Learn more
BioFresh 4+

BioFresh 4+

Get closer with BioFresh™ 4+ a powerful new way to eliminate bad breath naturally and effectively for up to four hours.

Learn more


A new approach to maintain a calm state of mind©.


Learn more
BioFresh Clean


Unleash your smile with BioFresh Clean a natural enzyme combination that keeps teeth clean by reducing oral biofilm.

Learn more

    1. Novozymes OneHealth Proprietary insights 2019, 2020, 2021, 2022.
    2. Own insights study + “She’s got guts survey” an independent study commissioned by Alimentary Health, March 2014
    3. O'Mahony et al. 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128: 541–551.
    4. Whorwell et al. 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American journal of gastroenterology. 101:1581–1590.
    5. Sabaté et al. 2022. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 28: 732-744
    6. Review Team. 2016: World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome, Journal of Clinical Gastroenterology. 50:704-713.
    7. Groeger et al. 2013. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 4:325-39.
    8. Hungin AP et al. 2013. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. Aliment Pharmacol Ther. 38:864-886.
    9. Brenner et al. 2009. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol.104:1033-49.
    10. Lyseng-Williamson. 2017. Bifidobacterium infantis 35624 as a probiotic dietary supplement: a profile of its use. Drugs & Therapy Perspectives. 33:368-374.
    12. Konieczna et al. 2012. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes. 3:261-6.
    13. Schiavi et al. 2016. The Surface-Associated Exopolysaccharide of Bifidobacterium longum 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local TH17 Responses. Appl Environ Microbiol. 82:7185-7196.
    14. Dunne et al. 1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 76:1-4.

Would you like to connect with us? 

Let us know if you have questions regarding our solutions or if you want to learn more about Rethinking Tomorrow within Human Health.

If you don't hear from us within 48 hours, then we apologize for dropping the ball and would like to know immediately: 

Thanks for getting in contact, one of our team will respond to your query shortly.